Lunai Bioworks has filed a second amended complaint in the U.S. District Court for the District of Delaware. The legal action targets six registered broker-dealers and two broker-dealer principals as defendants.

The filing represents an escalation in ongoing litigation involving the biotechnology firm. The defendants include multiple financial intermediaries registered with regulatory authorities.

Legal Proceedings

The case is being heard in the federal court system within Delaware. The second amended complaint suggests procedural updates or additional claims have been added to the initial filing.

The specific nature of the allegations against the broker-dealers and their principals is detailed in the court documents. The involvement of two principals indicates that individual liability may be sought alongside corporate responsibility.

No financial figures, revenue data, or balance sheet metrics were disclosed in the source material regarding this legal development.

Lunai Bioworks Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2), ensuring its continued listing on the exchange. The Nasdaq Stock Market LLC confirmed on June 11, 2026, that the company now meets the minimum bid price requirement of $1.00 per share. Following this disclosure, Lunai Bioworks shares soared 80.88% to $5.15 in after-hours trading on Tuesday. The stock closed the regular session up 9% at $2.84, with volume surging to 19.33 million shares, approximately 33.4 times the average daily volume of 578.99 thousand shares.

The resolution follows the company's adherence to terms set by the Nasdaq Hearings Panel in its decision and subsequent extension letters dated April 20, 2026, and May 12, 2026. Lunai Bioworks has now entered a mandatory one-year panel monitoring period. If the stock falls out of compliance with the minimum bid price requirement during this time, Nasdaq will issue a delisting determination letter directly, with no grace period or compliance plan permitted. The company, however, can request a new hearing before the panel to halt any suspension or delisting action.

Compliance Timeline

Trading Metrics

Lunai Bioworks has a market capitalization of $12.90 million. The stock's 52-week range includes a high of $31.75 and a low of $1.21. Over the past 12 months, the shares have dropped 90.11%. The Relative Strength Index (RSI) stands at 50.69, and short interest is 8.72%. Despite the recent surge, the stock is positioned close to its annual low, reflecting ongoing pressure and higher risk.